Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 101Active not recruiting 42Completed 34Not yet recruiting 22Terminated 20Suspended 6Withdrawn 2Enrolling by invitation 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 1CNS 1

Conditions

Medulloblastoma 1Leukemia, Myeloid, Acute 1Ependymoma 1Central Nervous System Neoplasms 1

Interventions

pembrolizumab 19Magnetic Resonance Spectroscopy 14Specimen Handling 13Cyclophosphamide 11fludarabine 10Radiotherapy 9Biopsy 9atezolizumab 7Nivolumab 7Radiation 6Gemcitabine 5fludarabine phosphate 4aldesleukin 4Prednisone 4Paclitaxel 4Etoposide 4Cytarabine 4Cisplatin 4Carboplatin 4Blood Specimen Collection 4Bevacizumab 4ALT-803 4venetoclax 3lenvatinib 3avelumab 3X-Rays 3Vincristine 3Surveys and Questionnaires 3Rituximab 3Phantoms, Imaging 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Azacitidine × 1 year × Clear all
NCT06466798 2026-01-08

Fourth Ventricular Administration of Immune Checkpoint Inhibitor (Nivolumab) and Methotrexate or 5-Azacytidine for Recurrent Medulloblastoma, Ependymoma, and Other CNS Malignancies

The University of Texas Health Science Center, Houston

Phase 1 Withdrawn
CNS

Ependymoma, Medulloblastoma, Central Nervous System Neoplasms

NCT06770257 2025-06-03

Daunorubicin, Cytarabine Liposomes Plus Venetoclax vs Azacitidine Plus Venetoclax in AML Patients Unfit for Intensive Chemotherapy

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Withdrawn
Other hematologic neoplasm

Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡